Abstract
Allogeneic hematopoietic cell transplantation (HCT) offers cure for some patients with hematological diseases but is associated with significant risk of morbidity and mortality. We investigated the incidence of AKI and its impact on transplant outcomes among 408 patients transplanted at Princess Margaret Hospital Cancer Centre, Toronto, Canada. The overall incidence of AKI at 100 days was 64.2%. Compared to those with no AKI, patients who developed AKI had inferior 2-y overall survival (OS), 44.7% vs. 62.4% (P = 0.0004), higher 2-y transplant related mortality (TRM) 36.8% vs. 18.7% (P = 0.0003), lower 2-y graft-vs-host disease (GVHD)- and relapse-free survival (GRFS), 21.0% vs. 39.8% (P = 0.0002), and higher 100-day grade 3–4 acute GVHD (aGVHD), 12.4% vs. 6.3% (P = 0.01). There was no difference in 2-y incidence of relapse between the AKI and non-AKI groups, 24.2% vs. 24.3% (P = 0.84), 100-day grade 2–4 aGVHD, 27.7% vs. 25.7 (P = 0.41) or 2-y moderate-severe chronic GVHD, 24.0% vs. 21.6% (P = 0.79). Patients who develop AKI within 100 days of HCT have inferior OS and GRFS with higher rates of TRM and grade 3–4 aGVHD. These results highlight the importance of close monitoring of renal function, multidisciplinary collaboration, and implementation of protective strategies throughout HCT to optimize transplant and kidney outcomes.
Similar content being viewed by others
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Krishnappa V, Gupta M, Manu G, Kwatra S, Owusu OT, Raina R. Acute kidney injury in hematopoietic stem cell transplantation: a review. Int J Nephrol. 2016;2016:5163789.
Shingai N, Morito T, Najima Y, Kobayashi T, Doki N, Kakihana K, et al. Early-onset acute kidney injury is a poor prognostic sign for allogeneic SCT recipients. Bone Marrow Transpl. 2015;50:1557–62.
Gavriilaki E, Sakellari I. Kidney disease after allogeneic hematopoietic cell transplantation: in search of the truth. Acta Haematol. 2020;143:405–6.
Renaghan AD, Jaimes EA, Malyszko J, Perazella MA, Sprangers B, Rosner MH. Acute kidney injury and CKD associated with hematopoietic stem cell transplantation. Clin J Am Soc Nephrol. 2020;15:289–97.
Shimoi T, Ando M, Munakata W, Kobayashi T, Kakihana K, Ohashi K, et al. The significant impact of acute kidney injury on CKD in patients who survived over 10 years after myeloablative allogeneic SCT. Bone Marrow Transpl. 2013;48:80–4.
Kogon A, Hingorani S. Acute kidney injury in hematopoietic cell transplantation. Semin Nephrol. 2010;30:615–26.
Kersting S, Koomans HA, Hené RJ, Verdonck LF. Acute renal failure after allogeneic myeloablative stem cell transplantation: retrospective analysis of incidence, risk factors and survival. Bone Marrow Transpl. 2007;39:359–65.
Sawinski D. The kidney effects of hematopoietic stem cell transplantation. Adv Chronic Kidney Dis. 2014;21:96–105.
Ando M. An overview of kidney disease following hematopoietic cell transplantation. Intern Med. 2018;57:1503–8.
Chang A, Hingorani S, Kowalewska J, Flowers ME, Aneja T, Smith KD, et al. Spectrum of renal pathology in hematopoietic cell transplantation: a series of 20 patients and review of the literature. Clin J Am Soc Nephrol. 2007;2:1014–23.
Clemmons AB, Bech CF, Pantin J, Ahmad I. Acute kidney injury in hematopoietic cell transplantation patients receiving Vancomycin and Piperacillin/Tazobactam versus Vancomycin and Cefepime. Biol Blood Marrow Transpl. 2018;24:820–6.
Jensen RR, Healy RM, Ford CD, Child B, Majers J, Draper B, et al. Amlodipine and calcineurin inhibitor-induced nephrotoxicity following allogeneic hematopoietic stem cell transplant. Clin Transpl. 2019;33:e13633.
da Silva JB, de Melo Lima MH, Secoli SR. Influence of cyclosporine on the occurrence of nephrotoxicity after allogeneic hematopoietic stem cell transplantation: a systematic review. Rev Bras Hematol Hemoter. 2014;36:363–8.
Tokgoz B, Kocyigit I, Polat G, Eser B, Unal A, Kaynar L, et al. Acute renal failure after myeloablative allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and relationship with the quantity of transplanted cells. Ren Fail. 2010;32:547–54.
Izzedine H, Launay-Vacher V, Deray G. Anti-viral drug induced nephrotoxicity. Am J Kidney Dis. 2005;45:21.
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of Cardiovascular Disease. Hypertension. 2003;42:1050–65.
Khalil AA, Khalil LT, Awidi A. Incidence, Risk Factors and Prognosis of Acute Kidney Injury Following Hematopoietic Stem Cell Transplant: A Pilot Study. Int J Stem Cells. 2019;12:43–50.
Sweiss K, Calip GS, Oh AL, Rondelli D, Patel PR. Renal dysfunction within 90 days of FluBu4 predicts early and late mortality. Bone Marrow Transpl. 2019;54:980–6.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.
Levey A, Stevens L, Schmid C, Zhang Y, Castro A, Feldman H, et al. A new equation to estimate Glomerular Filtration Rate. Ann Intern Med. 2009;150:604–12.
Fujii T, Uchino S, Takinami M, Bellomo R. Validation of the kidney disease improving global outcomes criteria for AKI and comparison of three criteria in hospitalized patients. Clin J Am Soc Nephrol. 2014;9:848–54.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.
Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333–8.
Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
Grant SW, Hickey GL, Head SJ. Statistical primer: multivariable regression considerations and pitfalls. Eur J Cardiothorac Surg. 2019;55:179–85.
Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2016;51:906–12.
Kagoya Y, Kataoka K, Nannya Y, Kurokawa M. Pretransplant predictors and posttransplant sequels of acute kidney injury after allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 2011;17:394–400.
Kemmner S, Verbeek M, Heemann U. Renal dysfunction following bone marrow transplantation. J Nephrol. 2017;30:201–9.
Sakaguchi M, Nakayama K, Yamaguchi H, Mii A, Shimizu A, Inai K, et al. Risk factors for acute kidney injury and chronic kidney disease following allogeneic hematopoietic stem cell transplantation for hematopoietic malignancies. Acta Haematol. 2020;143:452–64.
Liu H, Ding JH, Liu BC, Zhao G, Chen BA. Early renal injury after nonmyeloablative allogeneic peripheral blood stem cell transplantation in patients with chronic myelocytic leukemia. Am J Nephrol. 2007;27:336–41.
Parikh CR, McSweeney P, Schrier RW. Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant. Kidney Int. 2005;67:1999–2005.
Parikh CR, Sandmaier BM, Storb RF, Blume KG, Sahebi F, Maloney DG, et al. Acute renal failure after nonmyeloablative hematopoietic cell transplantation. J Am Soc Nephrol. 2004;15:1868–76.
Styczyński J, Tridello G, Xhaard A, Medinger M, Mielke S, Taskinen M, et al. Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study. Bone Marrow Transpl. 2021;56:1171–9.
Jerry Teng CL, Wang PN, Chen YC, Ko BS. Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: a mini-review. J Microbiol Immunol Infect. 2021;54:341–8.
Salas MQ, Prem S, Atenafu EG, Datt Law A, Lam W, Al-Shaibani Z, et al. Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. Bone Marrow Transplant. 2020;55:1773–83.
Pasic I, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, et al. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. Ann Hematol. 2020;99:1377–87.
Gupta S, Portales-Castillo I, Daher A, Kitchlu A. Conventional Chemotherapy Nephrotoxicity. Adv Chronic Kidney Dis. 2021;28:402–14.
Ferraz FTP, Marra AR, Hamerschlak N, de Souza Durão Junior M. The use of low doses of methotrexate during peri-cell infusion period may be a risk factor for acute kidney injury in patients subjected to hematopoietic stem cell transplantation. Ann Hematol. 2020;99:627–33.
Saner FH, Cicinnati VR, Sotiropoulos G, Beckebaum S. Strategies to prevent or reduce acute and chronic kidney injury in liver transplantation. Liver Int. 2012;32:179–88.
Mariotti J, Penack O, Castagna L. Acute Graft-versus-Host-Disease other than typical targets: between myths and facts. Biol Blood Marrow Transpl. 2020;27:115–24.
Sagou K, Fukushima N, Ukai S, Goto M, Ozeki K, Kohno A. Clinical usefulness of diagnostic criteria for transplant-associated thrombotic microangiopathy. Int J Hematol. 2020;112:697–706.
Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, et al. Incidence, risk factors for and outcomes of Transplant-Associated Thrombotic Microangiopathy. Br J Haematol. 2020;189:1171–81.
Jodele S. Complement in pathophysiology and treatment of Transplant-Associated Thrombotic Microangiopathies. Semin Hematol. 2018;55:159–66.
Piñana JL, Valcárcel D, Martino R, Barba P, Moreno E, Sureda A, et al. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience. Biol Blood Marrow Transpl. 2009;15:21–9.
Fraile P, Pilar F, Vazquez L, Lourdes V, Caballero D, Dolores C, et al. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant. Eur J Haematol. 2013;91:129–34.
Priluckiene J, Kriukelyte I, Jurgutis M, Trociukas I. [Chronic graft-versus-host disease presenting as nephrotic syndrome after allogenic hematopoietic stem cell transplantation]. Medicina (Kaunas). 2007;43:148–52.
Prasad M, Jain NG, Radhakrishnan J, ** Z, Satwani P. Risk factors for chronic kidney disease following acute kidney injury in pediatric allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021;56:1665–73.
Salas MQ, Pasic I, Remberger M, Novitzky-Basso I, Law AD, Lam W, et al. Improving safety and outcomes after allogeneic hematopoietic cell transplantation: a single centre experience. Transplant Cell Ther. 2022;28:265.e1–265.e9.
Author information
Authors and Affiliations
Contributions
All authors, KM, KP, GC, AK, SC, JM, and IP contributed to the study conception and design. Material preparation, data collection and analysis were performed by KM, KP, GC and SC under the supervision of IP. The manuscript was written by KM, revised by IP and all authors commented the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Madsen, K., Pelletier, K., Côté, G. et al. Acute kidney injury within 100 days post allogeneic hematopoietic cell transplantation is associated with increased risk of post-transplant complications and poor transplant outcomes. Bone Marrow Transplant 57, 1411–1420 (2022). https://doi.org/10.1038/s41409-022-01744-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-022-01744-0
- Springer Nature Limited
This article is cited by
-
Analysis of risk factors for fatal renal complications after allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation (2023)